Safety, tolerability, pharmacokinetics and effects of diet on AD16, a novel neuroinflammatory inhibitor for Alzheimer’s disease: a randomized phase 1 study

BACKGROUND: AD16 is a Class 1.1 new drug candidate for Alzheimer’s disease (AD), which has demonstrated potential benefits in AD by reducing neuroinflammation in preclinical studies. Herein, the pharmacokinetics (PK), safety, and tolerability of single and multiple-dose AD16 and the effect of food w...

Descripción completa

Detalles Bibliográficos
Autores principales: Peng, Daizhuang, Xu, Sumei, Zou, Ting, Wang, Yahui, Ouyang, Wenjuan, Zhang, Yalan, Dong, Chengmei, Li, Dai, Guo, Jie, Shen, Qiuying, Hu, Xiaolei, Zhou, Wenzhi, Li, Xiaomin, Qin, Qun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666448/
https://www.ncbi.nlm.nih.gov/pubmed/37996817
http://dx.doi.org/10.1186/s12916-023-03126-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10666448/
https://www.ncbi.nlm.nih.gov/pubmed/37996817
http://dx.doi.org/10.1186/s12916-023-03126-9

Ejemplares similares